
    
      This is a phase II, open-label, multicentre, randomised, two-arm study of 48 weeks duration.
      One hundred HIV infected individuals who have documented lipodystrophy at > 1 body/facial
      site and currently receiving zidovudine (ZDV) or stavudine (d4T) will be recruited.
    
  